Healthcare Industry News: drug-eluting stent
News Release - May 15, 2007
Stentys to Report Acute Results of Preclinical Testing With Its Bifurcated StentData to Be Disclosed at "EuroPCR 2007" Cardiovascular Congress in Barcelona, Spain
"We remain on schedule to begin first-in-man studies by mid-year." - Gonzague Issenmann, Co-Founder and CEO, Stentys
PARIS--(Healthcare Sales & Marketing Network)--May 15, 2007 --Stentys (www.stentys.com) announced today that the results of preclinical testing of its bifurcated stent will be reported on Thursday, May 24, 2007, at the "EuroPCR 2007" Cardiovascular Congress in Barcelona, Spain. Stentys will be part of the "Innovative Emerging Technologies" program, which will take place from 8:00 - 10:00 a.m. local time at The Forum - CCIB Convention Center.
Stentys is the first company to develop the next-generation of dedicated drug-eluting stents for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.
"We are extremely pleased with our acute preclinical results and look forward to reporting the data at one of the most important cardiology meetings of the year. And, we are also pleased that we remain on schedule to begin first-in-man studies by mid-year, as we move forward with our mission of making treatment of blocked coronary artery bifurcations as simple and effective as a conventional stenting procedure," said Stentys' CEO and co-founder, Gonzague Issenmann.
Bifurcation is the area where one main vessel branches out into two smaller vessels, one being the continuation of the main vessel, and the other often referred to as the side branch. Narrowings at a bifurcation site are quite common. Indeed, 18 percent of percutaneous coronary interventions involve a bifurcation stenosis. Of those, restenosis (re-occurrence of the blockage) occurs in 20-25 percent of bifurcations treated with drug-eluting stents (DES).
The patent-pending innovation of Stentys' bifurcated stent is that the stent-opening for the side branch can be created anywhere in the stent after it is implanted in the vessel. In short, the procedure's success is independent from accurate positioning. The Stentys procedure is performed in three simple steps: (1) Stentys is implanted in the main vessel with an approximate positioning, like a standard stent; (2) the cardiologist chooses the optimal location for the side branch opening by inserting a balloon through the stent mesh, which is a cath lab-standard procedure; and, (3) the balloon inflation disconnects the mesh and creates the opening -- the Stentys approach allows the in situ modeling of the stent to fit the patient's unique arterial anatomy.
The mission of "EuroPCR" is to contribute to the advancement of education and information about existing and new technologies in percutaneous interventions within the fields of coronary, peripheral, valve and non-coronary cardiac disease, cardio-thoracic surgery & vascular surgery, as well as imaging.
Based in Paris, Stentys intends to make treatment of blocked coronary artery bifurcations as simple and effective as a regular stenting procedure.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.